Use of matrix metalloproteinases, mutated and not mutated, for the preparation of pharmaceutical compositions, and mutated metalloproteinases with increased stability

The use of matrix metalloproteinases, mutated and not mutated, for the preparation of pharmaceutical compositions useful in the treatment of pathologies assiciated with an accumulation of matrix bio-polymers and/or an excess of TIMPs (Tissue Inhibitors MetalloProteinases) is described; mutated matrix metalloproteinases, in which at least an aminoacid residue in a definite position in the protein, has been mutated into a hydrophilic and/or charged aminoacidic residue, obtaining an increased stability toward autoproteolysis are also described.